Provention Bio (NASDAQ: PRVB) is one of 546 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Provention Bio to related companies based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, risk, earnings and dividends.

Valuation & Earnings

This table compares Provention Bio and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Provention Bio N/A -$26.48 million -2.48
Provention Bio Competitors $2.17 billion $229.91 million -3.77

Provention Bio’s competitors have higher revenue and earnings than Provention Bio. Provention Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Provention Bio and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Provention Bio N/A -109.82% -66.96%
Provention Bio Competitors -1,776.08% -105.48% -28.48%

Insider & Institutional Ownership

1.7% of Provention Bio shares are held by institutional investors. Comparatively, 46.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.8% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Provention Bio and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Provention Bio 0 0 3 0 3.00
Provention Bio Competitors 4499 12939 27592 991 2.54

Provention Bio currently has a consensus target price of $7.00, suggesting a potential upside of 137.29%. As a group, “Pharmaceutical preparations” companies have a potential upside of 52.48%. Given Provention Bio’s stronger consensus rating and higher probable upside, equities analysts plainly believe Provention Bio is more favorable than its competitors.

Summary

Provention Bio competitors beat Provention Bio on 7 of the 12 factors compared.

Provention Bio Company Profile

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company has a licensing and co-development agreement with Amgen Inc. for AMG 714. The company was incorporated in 2016 and is based in Oldwick, New Jersey.

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.